Parathyroid hormone (PTH) has been shown to have anabolic and catabolic effects on the skeleton, and in young racing horses the anabolic effects of PTH on bone might be of great importance in reducing the risk of skeletal injury during race training. The aim of this pilot study was to elucidate the effects of intermittent exogenous application of human parathyroid fragment (hPTH 1-37) on calcium homeostasis and bone turnover in resting horses. Five horses were used in this study. Horses were treated subcutaneously with hPTH (hPTH 1-37, 0.5 mg kg 21 BW) daily at 600 h over a period of 28 days. A foregoing control trial was conducted under the identical test protocol without hPTH application. Blood samples were taken at defined times for the control and hPTH treatment to analyze ionized Ca (Ca þ þ , AVL), total Ca (AAS), inorganic P i (flame photometry), intact PTH (RIA), osteocalcin (ELISA) and ICTP (carboxyterminal telopeptide of type-I collagen, RIA). Eight hours after hPTH application, blood ionized Ca þ þ (days 1 and 28) and plasma P i (days 1-28) increased significantly in comparison to the control. At day 1, 8 h after hPTH application, the decrease in intact plasma PTH was more pronounced after hPTH treatment than in the control, and plasma PTH levels were higher after treatment at day 14 (16 h post-injection, P , 0.05), day 18 (16 h post-injection, ns) and day 24 (0 h post-injection). There were no treatment-related differences in total plasma Ca and bone markers. Intermittent PTH administration in healthy horses affected Ca and P homeostasis as well as endogenous PTH secretion, but bone turnover was not affected during the treatment period of 28 days.
Introduction
Parathyroid hormone (PTH), an 84-amino acid polypeptide, is a major regulator of calcium homeostasis and bone cell metabolism in humans and other animals. PTH is partly responsible for increasing blood calcium levels by indirectly enhancing gastrointestinal absorption of calcium via vitamin D, increasing renal calcium reabsorption, and liberating calcium from the skeleton through a process of enhanced bone resorption 1 . However, depending on the mode of administration or secretion, PTH has varying effects on calcium metabolism and bone. Continuous infusion of PTH decreases bone mass by stimulating a net increase in bone resorption, whereas intermittent PTH administration increases bone mass by stimulating osteoblast differentiation and reducing osteoclast numbers, leading to an increase in bone formation 2, 3 . Furthermore, the local administration of hPTH geneactivated matrix (GAM) promoted bone formation in surgically induced bone defects in horses 4 . Anabolic effects on both cancellous and cortical bone mass induced by intermittent treatment with PTH analogues (full-length PTH 1-84 or PTH fragments 1-34, 1-37, 1-38) have been reported in healthy and osteopenic animals 5, 6 and in humans with osteoporosis [7] [8] [9] [10] [11] . Increased mechanical strength of the bones has also been observed along with enhanced bone mass. As PTH enhances bone formation, it is one of the most promising therapies for osteoporosis in postmenopausal women.
In horses, there are also several conditions which are accompanied by severe bone loss such as immobilization or long-term glucocorticoid therapy 12, 13 . Furthermore, Nielsen et al. (1998) 14 observed an initial decrease in optical bone density of the third metacarpus at the onset of training in Quarter Horses (60-120 days of training), which was followed by an increase in bone density in the course of the training programme. The decrease in bone mineral density might be related to a reduced stiffness and lowered resistance of the bone to strain. Accordingly, the majority of bone-related injuries occurred during the period when bone optical density of the third metacarpal was reduced 15 . However, the use of intermittent PTH treatment on mineral balance or bone has not been evaluated in the horse. Therefore, the purpose of this preliminary study was to determine the shortterm effects of intermittent administration of human PTH fragment (hPTH 1-37) on calcium homeostasis and bone markers in resting horses.
Material and methods

Horses
Five Standardbred geldings were used in this experiment; they were between 2 and 21 years of age and had a mean body weight of 459^35 kg. The horses were individually housed in box stalls. During the experiment, the horses were fed daily a constant basal diet formulated to meet energy and nutrient requirements according to GEH recommendations (1994) 16 for horses on maintenance (grass hay: 0.5 kg 100 kg 21 BW and sugar beet pulp: 0.5 kg 100 kg 21 BW; calculated daily energy intake: 57-70 MJ DE; daily Ca intake: 28-39 g; daily P intake: 6-8 g). The ration was divided into three portions and offered at 700, 1500 and 2300 h. During the experiment, the horses were bedded on wood shavings and had free access to water at all times.
This project was approved by the Ethics Committee on Animal Welfare of the Hannover District Government in accordance with German legislation on animal rights and welfare.
Experimental design
The experiment was divided into two trials. During the foregoing control trial, horses were fed the basal diet for 28 days. The control trial was followed by a treatment trial under the same protocol, except that the horses were treated subcutaneously with human PTH fragment 1-37 (hPTH 1-37, 0.5 mg kg 21 BW) once daily at 600 h over the whole period of 28 days (hPTH treatment). , Nobis Labordiagnostica GmbH, Endingen, Germany). Intact PTH in plasma was analyzed using a RIA (Intact PTH Immunoassay System, Nichols, Bad Nauheim, Germany). Osteocalcin in plasma was measured using an ELISA (Novo Calcin, Metra Biosystems, Osnabrück, Germany), and plasma ICTP was analysed with a RIA (ICTP-RIA, Orion Diagnostica, Espoo, Finland).
Statistical analysis
Data are presented as mean^SD. The effect of time and differences between the control and hPTH application were tested by analysis of variance for repeated measurements (ANOVA). When F values were significant, further analysis was made using the least significance difference test. Statistical significance was considered at P , 0.05.
Results
An increase in blood Ca
þ þ was determined 8 h after hPTH application, which was significant at days 1 and 28 (Table 1) . At 16 h post-injection, the increase was followed by a decrease in blood Ca þ þ (days 1, 14, 24 and 28; P , 0.05); levels of blood Ca þ þ levels were significantly lower at days 14 and 24 than in the control. Pooling the data for the five experimental days according to the different blood sampling times revealed higher blood Ca þ þ concentrations 8 h post-injection and lower blood Ca þ þ levels 16 h post-injection than in the control (Fig. 1) .
Unlike blood-ionized Ca þþ , there were no treatmentrelated changes in total Ca in plasma (data not shown).
Parallel to the rise in blood Ca þ þ , plasma P i increased in the hPTH group 8 h after hPTH application (Table 2) , and significantly at days 1, 24 and 28. For all treatment days, higher plasma P i were recorded for the hPTH group than for the control 8 h after hPTH application.
There was great variation in endogenous plasma PTH concentration among the horses (Table 3 ). The course of intact PTH in plasma was not consistent within the different experimental days, but at day 1, 8 h after hPTH administration, the decrease in plasma PTH was more pronounced for hPTH treatment, and higher plasma PTH levels were also observed at days 14 (16 h post-injection) and 24 (0 h post-injection) for hPTH treatment.
Plasma osteocalcin and ICTP showed some variations during the day, but these changes were not affected by hPTH treatment (Tables 4 and 5 ).
Discussion
PTH has been shown to have anabolic and catabolic effects on the skeleton. Continuous administration of exogenous PTH or secretion of PTH associated with hyperparathyroidism mediated an increase in osteoclast cell numbers and activity 17 . However, intermittent treatment with PTH, which currently requires once-a-day subcutaneous injection of human PTH analogues (full-length hPTH 1-84, hPTH 1-34, 1-37 and 1-38), resulted in profound increases in bone formation, bone density and bone mechanical strength in healthy and osteopenic humans and other animals 18 . Complementary to this, the treatment with hPTH (1-34) GAM stimulated bone formation in surgically induced bone defects in horses, and it was suggested that the local use of hPTH (1-34) GAM may be beneficial for the healing of cortical fractures in horses 4 . The mechanism whereby intermittent PTH administration increases bone mass is still poorly understood. Receptors for PTH are located on cells of osteoblast lineage, and administration of PTH fragments increases osteoblast numbers and osteoid formation in vitro 18 . Furthermore, the anabolic action of PTH on the skeleton is mediated by growth factors such as insulinlike growth factor (IGF) or transforming growth factor-b (TGF-b) in osteoblasts 18 . In this preliminary study, we used for the first time a human PTH fragment (hPTH 1-37) to study its effects on calcium homeostasis and bone markers in horses. The characteristic effects of PTH on bone are produced by the amino-terminal portion of the hormone (1-34, 1-37, 1-38). It is reported that the human PTH fragment does not show any structural differences from the equine one 19 . The dose of hPTH (1-37) chosen for this investigation was 0.5 mg kg 21 BW, which is comparable to the dosage in humans. In humans, the standard dose of hPTH fragments is 0.4 mg kg 21 BW, whereas considerably higher doses of the hormone fragment are used in rats (25-400 mg kg 21 BW). In the present study, the intermittent administration of hPTH (1-37) resulted in an increase in blood-ionized Ca þ þ and plasma P i 8 h after application. These significant changes, although not present on all treatment days, seemed to be the result of an enhanced bone resorption in which Ca and P are released from bone. An increase in plasma Ca has also been monitored in several studies in humans 7, 20 , but this was primarily related to very high PTH dosages.
On the other hand, the intermittent administration of PTH is known to stimulate the 1a-hydroxylation of 25-hydroxyvitamin D to 1,25(OH) 2 D in the kidney, and the active form of vitamin D facilitates the intestinal resorption of Ca and P, which also might increase blood mineral levels. In the present study, we did not analyze vitamin D or 1a-hydroxylase, but we did not find any differences in faecal Ca or P excretion depending on the treatment (data not shown). Furthermore, there is some evidence that, in contrast to other species, in the horse vitamin D does not appear to play a key role in regulating Ca and P homeostasis 21 . It is noteworthy that total plasma Ca was not affected by PTH treatment, which altered the relation between total Ca and ionized Ca þ þ in favour of the biologically active Ca þ þ 8 h after PTH administration. The relevance of this observation must be elucidated in further investigations. The endogenous intact PTH dropped 8 h after PTH injection, concomitant with the increase in blood Ca þ þ and plasma P i . Similar results have been obtained in humans: in one study, hPTH application was associated with a temporary reduction in the circulating levels of endogenous intact PTH not related to the circadian rhythm of PTH secretion 22 . As in our study, a decline in intact PTH has been associated with increased blood Means in the same row with unlike letters are different (P , 0.05); means in the same column with * are significantly different (P , 0.05) within the same day. z 0 h post-injection or 24 h post-injection on the previous day. Means in the same row with unlike lettes are different (P , 0.05); means in the same column with * are significantly different (P , 0.05) within the same day. z 0 h post-injection or 24 h post-injection on the previous day.
Ca þ þ 23 . Even more interesting is the report of a decline in intact PTH before any measurable rise in blood Ca þ þ 8 . The increase in ionized Ca þ þ is a probable explanation for the inhibition of the secretion of PTH 24, 25 , but Fujimi et al. (1991) 25 also showed a direct inhibitory effect of PTH fragment on parathyroid secretion in vitro.
The drop in intact PTH was followed by an increase in intact PTH 16 h after hPTH injection. One likely explanation is that the observed increase in plasma P i might be counter-regulated by endogenous PTH. An elevation of plasma P i results in the release of PTH, which acts directly on the renal tubule to decrease phosphate absorption and to increase urinary phosphate excretion, which allows rapid changes in plasma P i levels within minutes or hours 26 . The stimulation of endogenous PTH secretion might facilitate the effect of exogenous PTH on bone, as similar anabolic effects on bone mass were achieved by a transient increase of endogenous PTH secretion induced by hypocalcaemia in rats 27 . However, these changes in Ca homeostasis were not observed on each treatment day, a peculiarity that is poorly understood and needs further investigation.
In contrast to the treatment-related changes in Ca þ þ , P i and intact PTH, we determined no effect of PTH treatment on osteocalcin, a marker of bone formation, or ICTP, a marker of bone resorption. Osteocalcin is a small protein, which is synthesized by mature osteoblasts during the matrix mineralization phase, whereas ICTP is liberated during the degradation of type-I collagen 28 . These results contrast in part with studies in humans and rats, in which therapy with exogenous PTH was associated with increases in markers of bone turnover, providing evidence for a primary action of this agent to increase bone turnover. In humans, osteocalcin increased within 1 month of starting PTH administration 10 , whereas urinary n-telopeptide, a marker of bone resorption, did not rise until after 6 months 8 . Stimulation of bone turnover by intermittent PTH administration seemed to improve bone formation more than bone resorption, especially at sites of cancellous bone because of its high turnover rate.
In the present study, an increase in osteocalcin was expected, but more detailed knowledge of the dosage in horses is necessary for the optimum use of exogenous PTH to stimulate bone turnover and increase bone mass. On the other hand, the varying age of the horses might mask the effect of hPTH application on osteocalcin levels in the present study. Similar to results found in the literature, the youngest horse (2 years) showed the highest basal osteocalcin level, whereas the oldest horse (21 years) revealed the lowest basal osteocalcin concentration (50 and 16 mg l 21 , respectively). Bone markers such as osteocalcin or ICTP are negatively correlated with age and an important decrease during the first 30 months of life is noted [29] [30] [31] [32] . In the present study, the differences in basic values seemed to be accompanied by a different response to hPTH application. The youngest horse showed a 32% increase in plasma osteocalcin after hPTH application, whereas the older horses did not show any responses to exogenous PTH. A similar course was observed for ICTP, a marker that reflects bone resorption. The youngest horse had the highest basal ICTP levels, and the lowest ICTP concentration was found in the oldest horse (14.6 and 5.5 mg l 21 , respectively). However, an increase in ICTP concentration was noticed in the youngest horse after hPTH treatment (þ 28%) and nearly no changes were monitored for the older horses. It could be speculated that exogenous PTH application might have a more profound effect on the skeleton in growing horses than in adult animals, but the low number of horses does not allow a final conclusion. However, Backstrom et al. 4 found no age-related differences after the local treatment with hPTH (1-34) GAM in bone formation in horses.
In conclusion, intermittent exogenous PTH administration in healthy horses affected Ca and P homeostasis as well as endogenous PTH secretion, but did not clearly affect bone turnover, as measured by bone markers, during the treatment period of 28 days.
Further investigations are necessary to elucidate the implications of intermittent exogenous PTH application in stimulating bone turnover in healthy or osteopenic horses.
